Wellstar Health System and Augusta University Health System Announce Definitive Agreement for Statewide Partnership

On March 31, 2023, Wellstar Health System and Augusta University Health System (AUHS), with approval from both organizations’ boards, reached an agreement to form an innovative, new partnership that will create a broader affiliation with the university’s Medical College of Georgia (MCG).

Wellstar, AUHS and MCG share a mission to solve health care challenges across the state, and together, they will drive significant advances in clinical care, academic teaching and research in Georgia. By combining the best of community health care and academic medicine, the organizations will make a transformational impact on improving the health and wellbeing of each patient they serve –  creating a healthier future for Georgia.

To accomplish this, the partnership will focus on five key areas:

  • Access to Expertise:  Creating an ecosystem of care that provides the most advanced clinical care, innovated academic teaching models, and lifesaving research to all corners of the state and beyond.
  • Expanding the Pipeline of Clinicians:  Making significant investments to increase the number of clinicians trained in Georgia at the Medical College of Georgia.
  • Care Innovation:  Creating new and innovative clinical care offerings and models to enhance the health and well-being of patients we serve.
  • Pediatric Care:  Bringing Wellstar and AUHS’s exemplary pediatric care to more Georgians across the state through Children’s Hospital of Georgia and Wellstar’s dedicated pediatric care and emergency departments.
  • Digital Health:  Making significant investments in improving clinical IT, modernizing digital care centers, and adding remote care offerings backed by the academic medical expertise of the Medical College of Georgia.

Most of the day-to-day operations will stay the same, and patients will continue to access care as they currently do. The organizations are excited for the benefits this partnership will provide and are confident about the opportunity to transform health care through a better patient experience, more accessible care and better value.

For more information, read the  full announcement here.

March 24, 2026
Georgia Life Sciences is proud to be featured in the latest issue of Inside Medicine Magazine – Atlanta, highlighting the continued growth and impact of Georgia’s life sciences ecosystem.This inaugural issue represents something truly special. Atlanta’s healthcare and life sciences community is driven by innovation, collaboration, and outstanding leadership—and we’re honored to be part of this exciting launch. We’re proud to help showcase the people and organizations advancing healthcare across our region and beyond. Read our feature here: https://hubs.la/Q04876WJ0
March 24, 2026
B y Trevor Williams , March 24, 2026 | Global Atlanta More than 60 Belgian firms have found a home in Georgia, but nothing on this scale has yet been seen in the state. The amalgam of Belgian investment, carried out over a half-century, translates to about 5,000 current jobs. Gwinnett offered $174 million in incentives to win the project, including property tax abatements, fee waivers and utility improvements, according to Rowen. UCB is set to bring in artificial intelligence, advanced robotics and automation at the site. Biologics are therapies made from living organisms, promising cutting-edge research and manufacturing. Maria Thacker Goethe , president and CEO of Georgia Life Sciences , said the move gives state leaders even more impetus to work collaboratively to build Georgia’s talent pipeline “across every stage — from high school exposure and technical credentials to community college, university, and incumbent-worker upskilling.” “UCB’s decision underscores the strength of Georgia’s talent base, manufacturing capacity, and collaborative business climate, and it reflects the kind of long-term investment that helps build a more resilient U.S. biomanufacturing footprint,” Ms. Goethe told Global Atlanta in an email. Nine of the 16 FDA approvals for UCB drugs and therapies have come within the last three years, showing its prioritization of the U.S. market, where headcount has grown 73 percent since 2017 to 2,000 people. UCB’s products treat severe neurological and immunological conditions like epilepsy, lupus, Parkinson’s disease, rheumatoid arthritis and many more. Read the full article here: UCB Sticks With Georgia, Placing $2 Billion Bet on State’s Life Sciences Ecosystem - Global Atlanta
March 17, 2026
Georgia Life Sciences leads effort to establish bipartisan caucus focused on advancing the state’s growing life sciences economy
MORE POSTS